Sort   by:  
 Page size 
TranscriptomicsOvercoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
Unraveling the underlying mechanisms of cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) is of major importance as many tumors remain non-responsive or become resistant. Out microarray results suggest that resistant cells still exhibit RAS-MAPK pathway signaling contributing to ...
ORGANISM(S): Homo sapiens 
2014-09-18 | E-GEOD-61495 | biostudies-arrayexpress
TranscriptomicsRegulation of HB-EGF by miR-212 and acquired cetuximab-resistance in head and neck cancer
To determine the mechanism of cetuximab-resistance in head and neck cancer, a cetuximab-sensitive cell line (SCC1) and its cetuximab-resistant derivative (1Cc8) were analyzed for differentially expressed genes using DNA microarrays. 900 differentially expressed genes were found using the statistical...
ORGANISM(S): Homo sapiens 
2011-01-14 | E-GEOD-21483 | biostudies-arrayexpress
TranscriptomicsActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
HCC827 cells were grown in gradually increasing concentrations of cetuximab beginning at 0.1 ug/ml. Drug concentrations were slowly increased until the resistant cells were able to proliferate in 100 ug/ml of cetuximab. Individual clones of cetuximab resistant (CR; CR1 to CR4) cells were isolated an...
ORGANISM(S): Homo sapiens 
2011-11-23 | E-GEOD-30255 | biostudies-arrayexpress
TranscriptomicsGenomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples from 25 CRC patients...
ORGANISM(S): Homo sapiens 
2019-09-21 | E-MTAB-8340 | biostudies-arrayexpress
ProteomicsProteomics uncover EPHA2 in cetuximab resistant colorectal cancer cell lines as a potential novel therapeutic target
In metastatic colorectal cancer (mCRC), primary and acquired resistance against anti-EGFR targeted monoclonal antibodies, such as cetuximab (CET), were shown to be frequently caused by activating alterations in RAS genes (KRAS or NRAS). To this day no efficient second-line treatment options have eme...
ORGANISM(S): Homo sapiens (Human) 
2023-03-10 | PXD022072 | Pride
Epha2 Cetuximab resistance Proteomics 
TranscriptomicsTBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple Negative Breast Cancer
Abstract Background. Epidermal growth factor receptor (EGFR) is a targetable molecule in basal-like breast cancer, which comprises most “triple negative” breast cancer (TNBC), the only breast cancer subtype without established targeted therapy. Methods. In this randomized phase II trial, metastatic ...
ORGANISM(S): Homo sapiens 
2012-07-13 | E-GEOD-23428 | biostudies-arrayexpress
TranscriptomicsCetuximab resistant or sensitive head and neck cancer samples
10 cell lines (five cetuximab sensitive and five cetuximab resistant) were selected for gene copy number array analysis on the Affymetrix SNP 6.0 platform. 39 protein coding genes were amplified in cetuximab resistant cells and normal in sensitive cells, all present on genomic regions 11q22.1 or 5p1...
ORGANISM(S): Homo sapiens 
2012-12-01 | E-GEOD-36790 | biostudies-arrayexpress
TranscriptomicsInsulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma
Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) remains one of the most difficult cancers to treat with limited chemotherapeutic options. Here, we describe a patient with HNSCC who had complete response to methotrexate (MTX) after progressing on multiple cytotoxic agents; c...
ORGANISM(S): Homo sapiens 
2010-08-03 | E-GEOD-9600 | biostudies-arrayexpress
no omics definedTranscription profiling of human patients with advances metastatic colo-rectal cancer - phase II exploratory pharmacogenomics study of cetuximab monotherapy
Patients with metastatic colorectal cancer were enrolled for treatment with cetuximab monotherapy. Transcriptional profiling was conducted on RNA from pre-treatment metastatic site biopsies to identify genes whose expression correlates with best clinical responses. Experiment Overall Design: single...
ORGANISM(S): Homo sapiens 
2008-06-14 | E-GEOD-5851 | biostudies-arrayexpress
TranscriptomicsGene expression profile in relapsed or metastatic HNSCC patients treated with cetuximab and platinum therapy
First line chemotherapy with platinum and cetuximab is usually offered to RM-HNSCC pts. In the Extreme trial a median progression free survival (PFS) time of 5.6 months was reported. However, a small fraction of pts achieves a prolonged PFS (> than 12 months). Till now, no recognized predictive bio...
ORGANISM(S): Homo sapiens 
2016-08-01 | E-GEOD-65021 | biostudies-arrayexpress
Sort   by:  
 Page size